NCT07109817View on ClinicalTrials.gov

Desloratadine to Prevent Taxane-induced Peripheral Neuropathy in Patients With Breast Cancer

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

116

Participants

Timeline

Start Date

October 31, 2025

Primary Completion Date

January 31, 2029

Study Completion Date

January 31, 2030

Conditions
Breast CancerPeripheral Neuropathy
Interventions
DRUG

Desloratodine

Desloratadine 5mg PO daily for 12 weeks. Desloratadine is a long- acting tricyclic histamine antagonist with selective H1-receptor histamine antagonist activity. Desloratadine inhibited histamine release from human mast cells.

DRUG

Placebo

Placebo daily PO for 12 weeks. Placebo is a lactose filler covered by a capsule.

Trial Locations (1)

10467

Montefiore Medical Center, The Bronx

All Listed Sponsors
lead

Montefiore Medical Center

OTHER